This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
by Zacks Equity Research
PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
by Zacks Equity Research
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.
QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.
McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.
Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up
by Zacks Equity Research
Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.
GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS
by Zacks Equity Research
GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.
Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its first-quarter performance.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
by Zacks Equity Research
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
by Zacks Equity Research
GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.